Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Running, not enrolling · Phase 1
Conditions studied: MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
In brief
The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to treat those cancers.
Key facts
- Study ID
- NCT05838768
- Run by
- Novartis Pharmaceuticals
- People needed
- 123
- Starts
- 2023-06-27
- Expected to finish
- 2027-08-31
- Last updated by the study team
- 2026-03-24
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California LA — Los Angeles, California, United States
- UCSF — San Francisco, California, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Memorial Sloan Kettering — New York, New York, United States
- Columbia University Medical Ctr — New York, New York, United States
- Univ of TX MD Anderson Cancer Cntr — Houston, Texas, United States
- Novartis Investigative Site — Brussels, Belgium
- Novartis Investigative Site — Beijing, China
- Novartis Investigative Site — Guangzhou, China
- Novartis Investigative Site — Bordeaux, France
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Toulouse, France
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Tel Aviv, Israel
- Novartis Investigative Site — Milan, MI, Italy
- Novartis Investigative Site — Rozzano, MI, Italy
- Novartis Investigative Site — Kashiwa, Chiba, Japan
- Novartis Investigative Site — Oslo, Norway
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Seoul, South Korea
- Novartis Investigative Site — Barcelona, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Madrid, Spain
- Novartis Investigative Site — Valencia, Spain
- Novartis Investigative Site — Stockholm, Sweden
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.